WYMM Tour: Los Angeles
Thursday, November 14, 2024, 09:00 am-05:00 pm PST - Los Angeles, California
Generate ultra-rich data for answers with impact.
Who says you can’t see it all? With a comprehensive view of structural variants and methylation, nanopore technology powers the bigger and bolder research questions you’ve always wanted to ask.
Join us on Thursday, November 14, 2024 at the SLS Hotel Beverly Hills in Los Angeles to hear from local experts who are breaking new ground in human genomics, using nanopore technology.
What you're missing matters. Stay on top of what's next.
Aside from talks ranging from human genomics for rare disease, to sequencing for cancer research, the full-day agenda will include networking breaks, Q&A, product displays, and opportunities to engage with your peers and nanopore experts.
Please note that this is an in-person event.
There is no delegate fee for this event, but registration is required. Lunch and refreshments will be provided. Your place at this event will be confirmed via email from events@nanoporetech.com.
Full agenda coming soon.
Register
Agenda
09:00 am-05:00 pm EST | Agenda (subject to change) | Speaker |
|---|---|---|
09:00 am-09:30 am | Registration and breakfast | |
09:30 am-09:35 am | Welcome | Andy O'Shaughnessy, Oxford Nanopore Technologies |
09:35 am-10:00 am | Oxford Nanopore latest and greatest updates | Jim Brayer, Oxford Nanopore Technologies |
10:00 am-10:30 am | ONT sequencing is capable of detecting constitutional MLH1 methylation and linking to genetic haplotypes in Lynch syndrome | Megan P. Hitchins, Cedars-Sinai Medical Center |
10:30 am-11:00 am | Networking session | |
11:00am-11:30 am | Therapy resistance of high grade serous ovarian cancer established early in tumor development. | Michael Diaz, Cedars-Sinai Medical Center |
11:30 am-12:00 pm | Building an Artificial Kidney by Deconstructing and Reconstructing Development | Nils Lindström, University of Southern California |
12:00 pm-01:00 pm | Lunch | |
01:00 pm-01:30 pm | Epigenome alterations via glucose-regulated O-GlcNAcylation of DNMT1 | Dustin Schones, City of Hope |
01:30 pm-02:00 pm | Accelerating biotechnology with seamless sequencing | Jim Stapleton, Plasmidsaurus |
02:00 pm-02:15 pm | Networking session | |
02:15 pm-02:45 pm | Oxford Nanopore Bioinformatics updates | Rebecca Stubbs, Oxford Nanopore Technologies |
02:45 pm-03:00 pm | Closing Remarks | Andy O'Shaughnessy, Oxford Nanopore Technologies |
03:00 pm-04:00 pm | Networking session |
Speakers
Welcome
Andy O'Shaughnessy, Oxford Nanopore Technologies
...
)
Oxford Nanopore latest and greatest updates
Jim Brayer, Director, Strategic Product Management Americas, Oxford Nanopore Technologies
...
)
ONT sequencing is capable of detecting constitutional MLH1 methylation (epimutation) and linking methylation to extended genetic haplotypes in Lynch syndrome cases.
Megan P. Hitchins, Professor, Director for Translational Genomics, Department of Biochemistry, Cedars-Sinai Medical Center
Professor Megan Hitchins is a cancer geneticist and epigeneticist with a research focus on unusual o...
)
The mutation and clonality profile of genomically unstable high grade serous ovarian cancer is established early in tumor development and conserved throughout therapy resistance.
Michael Diaz, Bioinformatician, Cedars Sinai
I am a recent Ph.D. graduate from Cedars Sinai that studied genomic profiling of matched primary and...
)
Building an Artificial Kidney by Deconstructing and Reconstructing Development
Nils Lindstrom, Assistant Professor in Stem Cell Biology and Regenerative Medicine Director CIRM ASCEND Shared Resource Laboratory Faculty Director Optical Imaging Facility Broad CIRM Center for Regenerative Medicine and Stem Cell Research , University of Southern California
Dr. Nils Lindström earned his Ph.D. in developmental biology at the University of Edinburgh detailin...
)
Epigenome alterations via glucose-regulated O-GlcNAcylation of DNMT1
Dustin Schones, Associate Professor, Department of Diabetes Complications and Metabolism, City of Hope
Dr. Schones is interested in the epigenetic regulation of the genome and how epigenetic modification...
)
Accelerating biotechnology with seamless sequencing
James Stapleton, CTO, Plasmidsaurus
Jim Stapleton is a co-founder and CTO of Plasmidsaurus. He has a PhD in chemical engineering and is ...
)
Calling disease variants in human samples using automated EPI2ME end-to-end workflows
Rebecca Stubbs, Genomic Applications Bioinformatician, Oxford Nanopore Technologies
...